Benzinga | Nov 17, 2021 08:34AM EST

Lantheus Holdings Announces Presentations Featuring PYLARIFY (Piflufolastat F 18), Its PSMA-Targeted Prostate Cancer Imaging Agent, At Key Scientific Meetings

Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today poster presentations featuring PYLARIFY(r) (piflufolastat F 18) data from the Company's Phase 3 CONDOR study at the upcoming Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), which will be held from November 28 - December 2, 2021 in Chicago, IL and the 22nd Annual Meeting of the Society for Urologic Oncology (SUO), which will be held from December 1-3, 2021 in Orlando, FL.



Details for the RSNA presentation are as follows:

Date/Time: November 30, 2021 4:30 -- 5:00 PM CT

Session Title: Genitourinary Tuesday Poster Discussions (Session ID: GU03-D)

Title: Assessment of Diagnostic Performance with 18F-DCF-PYL PET/CT in Men with Suspected Recurrence of Prostate Cancer: A CONDOR Study Subanalysis Comparing Central and Local Reader Results

Presenter: Kenneth L. Gage, MD, PhD, Diagnostic Imaging and Interventional Radiology

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Abstract No: 8988

Details for the SUO presentation are as follows:

Date/Time: Friday, December 3, 2021 3:00 -- 4:00 PM ET

Title: Diagnostic Performance of Piflufolastat F 18 PET/CT in Men with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A CONDOR Study Subanalysis

Presenter: Peter Carroll, MD, MPH, Professor of Urology at University of California San Francisco

Abstract No: 219

About PYLARIFY(r) (piflufolastat F 18) Injection

PYLARIFY(r) (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. For men with prostate cancer, PYLARIFY PET combines the accuracy of PET imaging, the precision of PSMA targeting and the clarity of an F 18 radioisotope for superior diagnostic performance. The recommended PYLARIFY dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection.1-6

PYLARIFY(r) (piflufolastat F 18) Injection

Indication

PYLARIFY(r) (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

* with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.